Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too

One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.